<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00719316</url>
  </required_header>
  <id_info>
    <org_study_id>NL19926.041.07</org_study_id>
    <nct_id>NCT00719316</nct_id>
  </id_info>
  <brief_title>Aliskiren and Muscle Sympathetic Nerve Activity</brief_title>
  <acronym>MSNA</acronym>
  <official_title>Effect of Aliskiren on Muscle Sympathetic Nerve Activity (MSNA) in Hypertensive Patients With Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The central hypothesis of this project is that Aliskiren causes a substantial decrease in
      MSNA in hypertensive patients with CKD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiovascular (CV) morbidity and mortality are frequently occurring problems in chronic
      kidney disease (CKD) patients. Apart from the so called traditional risk factors, also risk
      factors more or less specific to CKD contribute in the pathogenesis of these problems. There
      is strong evidence that the sympathetic hyperactivity, which often characterizes CKD, is one
      such factor. Previously, we have shown that angiotensin converting enzyme inhibitors (ACEi)
      and angiotensin II receptor blockers (ARB) reduce but not normalize this sympathetic
      hyperactivity. We re-analysed the cohort of patients who were investigated in the past and
      subsequently treated according to present guidelines. The results show that, despite of
      treatment, the unfavourable relation between sympathetic hyperactivity and clinical outcome
      still exits. This might mean that treatment is insufficient. In present study, we want to
      study the effect of Aliskiren 300mg on sympathetic nerve activity.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2008</start_date>
  <completion_date type="Anticipated">January 2010</completion_date>
  <primary_completion_date type="Anticipated">July 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Normalisation of muscle sympathetic nerve activity</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood pressure and Blood tests</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <condition>Hypertension</condition>
  <condition>Muscle Sympathetic Nerve Activity</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive Aliskiren 300mg for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>4 weeks no antihypertensive medication</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aliskiren</intervention_name>
    <description>Aliskiren 300mg per day for 6 weeks</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Rasilez 300mg per day</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with stable chronic kidney disease and hypertension: i.e. using
             antihypertensive drugs and/or blood pressure &gt; 145/90 mmHg when off medication.

          -  Patients on ACE inhibitor or ARB

        Exclusion Criteria:

          -  Patients with diabetes mellitus

          -  Patients on renal replacement therapy

          -  Pregnant patients Using of antihypertensive which cannot be stopped

          -  Patients on immunosuppressive therapy and active nephrotic syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>P. J. Blankestijn, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laima Siddiqi, MD</last_name>
    <phone>+ 31 88 755 7329</phone>
    <email>l.siddiqi@umcutrecht.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Medical Center utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Laima Siddiqi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2008</study_first_submitted>
  <study_first_submitted_qc>July 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2008</study_first_posted>
  <last_update_submitted>January 13, 2010</last_update_submitted>
  <last_update_submitted_qc>January 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. P. J. Blankestijn</name_title>
    <organization>UMC Utrecht</organization>
  </responsible_party>
  <keyword>Renin inhibitor</keyword>
  <keyword>Patients</keyword>
  <keyword>ACE inhibitor or ARB</keyword>
  <keyword>Chronic Kidney Disease</keyword>
  <keyword>Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

